KR100569089B1 - Composition having brain function and congnition enhancing activity - Google Patents
Composition having brain function and congnition enhancing activity Download PDFInfo
- Publication number
- KR100569089B1 KR100569089B1 KR1020020042740A KR20020042740A KR100569089B1 KR 100569089 B1 KR100569089 B1 KR 100569089B1 KR 1020020042740 A KR1020020042740 A KR 1020020042740A KR 20020042740 A KR20020042740 A KR 20020042740A KR 100569089 B1 KR100569089 B1 KR 100569089B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- present
- brain
- function
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 230000003925 brain function Effects 0.000 title claims abstract description 16
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 22
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 18
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 18
- 230000003920 cognitive function Effects 0.000 claims abstract description 17
- 240000002045 Guettarda speciosa Species 0.000 claims abstract description 14
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 14
- 235000011197 perejil Nutrition 0.000 claims abstract description 11
- 240000009164 Petroselinum crispum Species 0.000 claims abstract 2
- 239000002775 capsule Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 235000015872 dietary supplement Nutrition 0.000 claims description 8
- 235000008216 herbs Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000019771 cognition Effects 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims 1
- 241000411851 herbal medicine Species 0.000 abstract description 16
- 241000209020 Cornus Species 0.000 abstract description 14
- 244000000231 Sesamum indicum Species 0.000 abstract description 13
- 235000003434 Sesamum indicum Nutrition 0.000 abstract description 13
- 210000004556 brain Anatomy 0.000 abstract description 8
- 240000008932 Sison amomum Species 0.000 abstract description 5
- 235000011192 Sison amomum Nutrition 0.000 abstract description 5
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 4
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 3
- 230000001149 cognitive effect Effects 0.000 abstract description 2
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 13
- 230000002490 cerebral effect Effects 0.000 description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- 241000208317 Petroselinum Species 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 229930195712 glutamate Natural products 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000001054 cortical effect Effects 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 4
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 4
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 206010029350 Neurotoxicity Diseases 0.000 description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 description 4
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000003412 degenerative effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000007135 neurotoxicity Effects 0.000 description 4
- 231100000228 neurotoxicity Toxicity 0.000 description 4
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 4
- 229960002646 scopolamine Drugs 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 240000001810 Angelica gigas Species 0.000 description 3
- 235000018865 Angelica gigas Nutrition 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 244000241872 Lycium chinense Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000012223 aqueous fraction Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- -1 cell membranes Proteins 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007370 cognitive improvement Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 241000218691 Cupressaceae Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 2
- 210000005037 parasympathetic nerve Anatomy 0.000 description 2
- 238000011302 passive avoidance test Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003478 temporal lobe Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 1
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VNPMDUDIDCXVCH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(3-piperazin-1-ylpropyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(CCCN2CCNCC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VNPMDUDIDCXVCH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- HLVVITIHAZBPKB-UHFFFAOYSA-N 9-amino-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC=C2C(N)=C(C(O)CCC3)C3=NC2=C1 HLVVITIHAZBPKB-UHFFFAOYSA-N 0.000 description 1
- 229940124596 AChE inhibitor Drugs 0.000 description 1
- 206010000372 Accident at work Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940122459 Glutamate antagonist Drugs 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000253121 Inula britannica Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 235000000365 Oenanthe javanica Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 240000002924 Platycladus orientalis Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 229930186706 Puerarin-xyloside Natural products 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 241000758742 Saururaceae Species 0.000 description 1
- 241000534017 Saururus chinensis Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000019714 Triticale Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000016253 exhaustion Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930193974 gastrodin Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000020687 goji berry extract Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229940117336 parsley extract Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229930182487 phenolic glycoside Natural products 0.000 description 1
- 150000007950 phenolic glycosides Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- NAAXIGQVODQJOV-PXYOAQHISA-N puerarin xyloside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C(C1=C(C(C(C=2C=CC(O)=CC=2)=CO1)=O)C=C1)=C1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)CO1 NAAXIGQVODQJOV-PXYOAQHISA-N 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000007853 structural degeneration Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229950001843 velnacrine Drugs 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
- 241000228158 x Triticosecale Species 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 뇌기능 및 인지 기능 개선 활성을 갖는 조성물에 관한 것으로서, 보다 상세하게는 삼백초, 오미자, 돌미나리, 당귀, 산수유, 선복화, 측백엽, 갈근, 천마 및 구기자로 이루어진 군에서 선택되는 2종 이상의 생약의 알콜 추출물을 포함하는 뇌기능 및 인지 기능 개선용 조성물에 관한 것이다. The present invention relates to a composition having brain and cognitive function-improving activity, and more particularly, at least two selected from the group consisting of three hundred seconds, Schisandra chinensis, parsley, Angelica, Cornus, Sesame, Sesame leaf, Brown root, Cheonma and Goji. It relates to a composition for improving brain function and cognitive function comprising an alcohol extract of the herbal medicine.
삼백초, 오미자, 돌미나리, 당귀, 산수유, 선복화, 측백엽, 갈근, 천마, 구기자, 뇌기능, 인지 기능 개선Three hundred seconds, Schisandra chinensis, Stone parsley, Angelica, Cornus, Coniferous, White leaf, Brown root, Cheonma, Wolfberry, Brain function, Improving cognitive function
Description
본 발명은 뇌기능 및 인지 기능 개선 활성을 갖는 조성물에 관한 것으로서, 보다 상세하게는 삼백초, 오미자, 돌미나리, 당귀, 산수유, 선복화, 측백엽, 갈근, 천마 및 구기자로 이루어진 군에서 선택되는 2종 이상의 생약의 알콜 추출물을 포함하는 뇌기능 및 인지 기능 개선용 조성물에 관한 것이다. The present invention relates to a composition having brain and cognitive function-improving activity, and more particularly, at least two selected from the group consisting of three hundred seconds, Schisandra chinensis, parsley, Angelica, Cornus, Sesame, Sesame leaf, Brown root, Cheonma and Goji. It relates to a composition for improving brain function and cognitive function comprising an alcohol extract of the herbal medicine.
최근 노인 인구가 늘어남에 따라 퇴행성 뇌신경계 질환, 특히 노인성 치매 환자도 급증하고 있다. 노인성 치매는 기억력의 상실, 학습능력의 저하가 주 증상으로 환자는 물론 그 가족까지 함께 커다란 고통을 겪어야 하는 질환이다. 이미 노인 인구 증가로 인한 치매 환자의 증가가 사회적인 문제로 대두되어 이의 예방 및 치료에 대한 관심은 날로 높아져가고 있으나 아직까지도 이렇다 할 치료제가 개발되어 있지 않아 그 심각성이 더욱 크게 부각되고 있는 질환이다. Recently, as the elderly population increases, the number of patients with degenerative neurological diseases, especially senile dementia, is increasing rapidly. Geriatric dementia is a condition in which memory loss and deterioration in learning ability are the main symptoms and patients and their families must suffer a lot together. As the number of dementia patients due to the increase of the elderly population has become a social problem, the interest in the prevention and treatment of them is increasing day by day, but the severity is getting more serious because there are no treatments yet developed.
퇴행성 뇌신경계 질환은 노화에 의한 뇌신경세포의 구조적 퇴화, 순환기 장애 등과 같은 성인병에 기인한 2차적 증상, 또는 교통사고, 산업재해, 일산화탄소 중독 등 물리적, 기계적 요인에 의하여 뇌가 손상을 입으면 일어날 수 있다. 즉, 뇌로 공급되는 혈류량이 감소되거나 차단되어 뇌조직이 저산소, 저포도당 상태가 되면 정상대사를 할 수 없어 뇌조직은 회복될 수 없는 손상을 입게 된다. 이러한 경우는 발작(stroke), 외상(trauma) 및 허혈성 손상(ischemic injury) 뿐만 아니라 퇴행성 뇌신경계 질환에서 아주 흔하게 볼 수 있다. Degenerative cerebral nervous system disease may occur when the brain is damaged by secondary symptoms caused by adult diseases such as structural degeneration of the neuronal cells due to aging, circulatory disorders, or physical and mechanical factors such as traffic accidents, industrial accidents, and carbon monoxide poisoning. . In other words, when the blood flow to the brain is reduced or blocked, brain tissue becomes hypoxic and low glucose, so that normal metabolism cannot be performed, and the brain tissue is irreparably damaged. Such cases are very common in stroke, trauma and ischemic injury as well as in degenerative neurological diseases.
뇌조직의 손상은 크게 두 가지 기전에 의한 것으로 알려져 있다. 첫 번째로는 세포막 전압의 변화에 의한 흥분성 아미노산 유리의 증가에 의한 것이며, 두 번째로는 직접적인 산화성 스트레스(oxidative stress)에 의한 것이다. 뇌조직 손상의 원인인 산화성 스트레스를 유발하기 위해서는 H2O2나 글루타메이트를 독성물질로 이용한다. H2O2는 활성산소 화합물류(reactive oxygen species) (ROS)의 하나로 세포 내외에서 다양한 원인에 의해 생성되며 대사과정 중에 또 다른 ROS의 생성을 유발한다. 이러한 ROS는 산화성 스트레스를 일으켜 세포내 단백질, 세포막, DNA 등에 손상을 입혀 결국은 세포를 손상시키며 세포막 투과성이 높아 주위의 세포에도 독성을 나타낸다. 세포는 이러한 산화 스트레스에 대하여 항산화물질과 항산화효소와 같은 다양한 방어기전을 가지고 있다. 세포내 항산화물질로는 GSH가 대표적인데 GSH는 대부분 환원형 GSH로 존재하고 ROS가 증가하면 GSSG로 변화하며 따라서 GSSG의 증가는 산화성 스트레스의 지표가 된다. Brain tissue damage is known to be largely due to two mechanisms. The first is due to the increase in excitatory amino acid release due to the change in cell membrane voltage, and the second is due to direct oxidative stress. To induce oxidative stress, which causes brain tissue damage, H 2 O 2 or glutamate is used as a toxic substance. H 2 O 2 is one of the reactive oxygen species (ROS), which is produced by various causes in and out of cells, and induces the production of another ROS during metabolism. These ROS cause oxidative stress and damage intracellular proteins, cell membranes, DNA, and the like, eventually damaging cells and having high cell membrane permeability, which is toxic to surrounding cells. Cells have various defense mechanisms, such as antioxidants and antioxidant enzymes, against these oxidative stresses. The intracellular antioxidants are represented by GSH. Most of GSH exists as reduced GSH, and when ROS is increased, it is changed to GSSG. Therefore, the increase of GSSG is an indicator of oxidative stress.
또한 최근의 연구에 의하면 발작(stroke), 외상(trauma) 및 허혈성 손상(ischemic injury)의 경우 글루타메이트가 이온향성 수용체(ionotrophic receptor)를 활성화시킴으로써 산화성 스트레스를 일으켜 글루타메이트성 신경에 이상을 초래하여 발병되는 것으로 알려지고 있다. 뇌조직에서의 혈류량이 감소되면 신경 접합부에서 글루타메이트의 유리가 증가되며, 신경세포 안으로의 유입은 감소되어 세포 외에서의 글루타메이트의 농도가 급속히 증가되면서 독성을 유발시켜 신경세포는 결국 사멸하게 된다. 글루타메이트에 의한 신경독성은 글루타메이트의 길항물질, Na+ 및 Ca2+ 채널 차단제, 항산화제, 유리 라디칼체인 차단제(free radical chain breakers) 및 잔틴 데하이드로지네이스(xanthine dehydrogenase)로부터 잔틴 옥시데이즈로의 전환을 억제하는 효소인 안티프로티에이즈(antiproteases) 등에 의하여 방지될 수 있으나 특히, NMDA 수용체에 대한 길항물질이 효과적이다. Recent studies have also shown that in the case of stroke, trauma and ischemic injury, glutamate activates the ionotrophic receptor, causing oxidative stress and causing abnormalities in the glutamate nerves. It is known. As the blood flow in the brain tissues decreases, the release of glutamate increases at the nerve junctions, and the influx into the neurons decreases, causing a rapid increase in the concentration of glutamate outside the cells, causing toxicity and killing the nerve cells. Neurotoxicity by glutamate is the conversion of glutamate antagonists, Na + and Ca 2+ channel blockers, antioxidants, free radical chain breakers and xanthine dehydrogenase to xanthine oxidases It can be prevented by antiproteases (enzymes) that inhibits, but in particular, antagonists to NMDA receptors are effective.
본 발명자들은 그 동안 민간이나 한방에서 널리 이용되어오던 천연물을 대상으로 뇌신경세포 보호 활성이나 인지개선 활성을 검색하던 중 다수의 천연물들이 유의성 있는 활성을 보임을 알았다. 특히 본 발명자들에 의한 대한민국 특허출원 제2000-73927호, 2000-61687호 및 2000-61676호 등에는 당귀, 삼백초 및 오미자 등의 생약이 뇌신경세포 보호 활성을 갖고 있음이 개시되어 있다. 그러나, 이들 각각의 천연물의 경우 임상에 적용할 정도로 우수한 효과를 갖는 천연물이 없어, 본 발명에서는 이들 천연물들을 활용하여 뇌기능이나 인지 기능 개선 기능을 갖는 새로운 복합 조성물을 개발하여 본 발명을 완성하였다. The present inventors have found that many natural products show significant activity while searching for neuroprotective activity or cognitive improvement activity against natural products that have been widely used in folk medicine or oriental medicine. In particular, Korean Patent Application Nos. 2000-73927, 2000-61687, and 2000-61676 by the present inventors disclose that herbal medicines such as Angelica gigas, Triticales and Schisandra chinensis have brain neuronal cell protective activity. However, in the case of each of these natural products do not have a natural product having an excellent effect enough to apply to the clinical, the present invention has completed the present invention by developing a new composite composition having a brain function or a cognitive function improving function utilizing these natural products.
본 발명의 목적은 뇌기능 및 인지 기능 개선 기능을 갖는 새로운 조성물 및 이들 포함하는 식품첨가물 또는 건강보조식품을 제공하는 것이다. An object of the present invention is to provide a new composition having a brain function and cognitive function improving function and a food additive or dietary supplement comprising the same.
본 발명의 첫 번째 면은 삼백초, 오미자, 돌미나리, 당귀, 산수유, 선복화, 측백엽, 갈근, 천마 및 구기자로 이루어진 군에서 선택되는 2종 이상의 생약의 알콜 추출물을 포함하는 뇌기능 및 인지 기능 개선용 조성물을 제공한다. The first aspect of the present invention for improving brain function and cognitive function including alcohol extracts of two or more herbal medicines selected from the group consisting of three hundred seconds, Schisandra chinensis, stone parsley, Angelica, Cornus, Sesame, Sesame leaf, Brown root, Cheonma and Goji To provide a composition.
상기 본 발명의 조성물은 각각의 생약이 1∼5중량부인 것이 바람직하다. It is preferable that the composition of this invention is 1-5 weight part of each herbal medicine.
본 발명은 또한 생약이 3종 이상이고, 삼백초, 오미자, 돌미나리 및 당귀로 이루어진 군에서 선택되는 뇌기능 및 인지 기능 개선용 조성물을 제공한다.The present invention also provides a composition for improving brain function and cognitive function selected from the group consisting of three or more herbs, three hundred seconds, Schisandra chinensis, parsley and Angelica.
본 발명은 또한 상기 알콜 추출물을 유기용매 또는 물로 분획하거나, 이 분획물을 컬럼크로마토그래피하여 제조한 뇌기능 및 인지 기능 개선용 조성물을 제공한다. The present invention also provides a composition for improving brain function and cognitive function, wherein the alcohol extract is fractionated with an organic solvent or water, or the fraction is prepared by column chromatography.
본 발명의 두 번째 면은 상기 뇌기능 및 인지기능 개선용 조성물을 함유하는 뇌기능 및 인지 기능 개선 효과를 나타내는 식품첨가물 또는 건강보조식품을 제공한다. 상기 건강보조식품은 정제, 캅셀제, 분말제, 과립제, 액상제 및 환제로 구성된 군으로부터 선택되는 것이 바람직하다. The second aspect of the present invention provides a food additive or health supplement containing the brain and cognitive function improving composition containing the brain and cognitive function improving effect. The health supplement is preferably selected from the group consisting of tablets, capsules, powders, granules, liquids and pills.
이하, 본 발명을 상세하게 설명한다.EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated in detail.
본 발명은 삼백초, 오미자, 돌미나리, 당귀, 산수유, 선복화, 측백엽, 갈근, 천마 및 구기자로 이루어진 군에서 선택되는 2종 이상, 바람직하게는 3종의 생약의 알콜 추출물을 포함하는 뇌기능 및 인지 기능 개선용 조성물을 제공한다. 본 발명 의 알콜 추출물을 위해 사용될 수 있는 알콜은 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올 등의 C1-4의 저급알콜이 바람직하다. The present invention is brain function and cognition comprising alcohol extracts of two or more, preferably three herbal medicines selected from the group consisting of three hundred seconds, Schisandra chinensis, parsley, Angelica, Cornus, Coniferous, baekryeop, brown root, Cheonma and Goji Provided is a composition for improving function. The alcohol which can be used for the alcohol extract of the present invention is preferably C 1-4 lower alcohols such as methanol, ethanol, propanol, isopropanol, butanol and the like.
본 발명의 구성요소인 삼백초(Saururus chinensis)는 삼백초과(Saururaceae)에 속하는 다년생 초본으로 풀 전체 또는 뿌리나 잎이 풍독(風毒), 이뇨(利尿), 수종(水腫), 임질(淋疾), 간염(肝炎), 폐렴(肺炎), 변독(便毒), 고혈압(高血壓) 등의 치료에 민간에서 사용해 왔다. 삼백초는 중국의 고대 의약서인 명의별록(名醫別錄)에 수재되어 있으며, 7∼9월에 지상부를 채집하여 햇빛에 말려 사용한다. 미(味)는 고신(苦辛)하고, 성(性)은 한(寒)하며, 간(肝), 폐(肺), 신경에 들어간다. 습열(濕熱), 청리(淸利), 소독(消毒), 해독(解毒)의 효능이 있는 것으로 알려져 있으며, 부종(浮腫), 각기(脚氣), 황달(黃疸), 임질(淋疾), 대하(帶下) 등을 치료하는데 이용했다. Three hundred herb (Saururus chinensis), a component of the present invention, is a perennial herb belonging to three hundred (Saururaceae) grasses or roots or leaves of wind poison (wind), diuresis, water species, gonorrhea, hepatitis (肝炎), pneumonia (변), venom (便 毒), high blood pressure (高血壓) has been used in the private sector. Three hundred seconds are stored in the ancient Chinese medicine book, Ming-Seok, which is collected in July and September, and dried in sunlight. Beauty is high, sex is cold, and enters the liver, lungs, and nerves. It is known to have the effects of moist heat, clearing, disinfection, and detoxification. Edema, each, jaundice, gonorrhea, and lobster It was used to treat back and back).
본 발명의 구성요소인 오미자(Schizandra chinensis)는 예로부터 민간에서 강장이나 간장보호 목적으로 사용되었으며, 디벤조사이클로옥탄 리그난계 성분이 주를 이루며, 그 활성에 대하여서도 많은 연구가 진행되어 왔다. 오미자로부터 분리된 디벤조사이클로옥탄 리그난계 성분의 중요한 활성으로 간장보호 작용, 그 외 항암, 항염, 항바이러스 작용 등이 보고되고 있다. Schizandra chinensis, a component of the present invention, has been used for the purpose of tonic and soy sauce protection in the folklore since ancient times, and mainly dibenzocyclooctane lignan-based components, and many studies have been conducted on its activity. Hepatoprotective, anti-cancer, anti-inflammatory and antiviral effects have been reported as important activities of dibenzocyclooctane lignan-based components isolated from Schisandra chinensis.
본 발명의 구성요소인 돌미나리(Oenanthe javanica)는 겨자과의 다년생 초본으로 서식지는 아시아와 유럽이며, 그 중에서도 특히 우리나라와 일본, 중국에서 주로 사용되고 있다. 돌미나리의 구성성분으로는 단백질이 가장 많이 함유되어 전 체 건조량의 30∼40%를 차지하여 지방함량은 대체로 적어서 1∼3%에 불과하여, 또한 정미 성분으로 각종 아미노산이 풍부하며, 이들 외에도 아스코르브산 등의 비타민과 칼슘, 인 칼륨 등의 무기질이 다량 함유되어 있다. Oenanthe javanica, which is a component of the present invention, is a perennial herb of mustard family, and its habitat is Asia and Europe, and is especially used in Korea, Japan, and China. As a component of stone parsley, it contains the most protein, accounting for 30-40% of total dry matter, and the fat content is generally small, only 1 to 3% .It is also rich in various amino acids as a taste ingredient. Vitamins and minerals such as calcium and potassium are contained in a large amount.
본 발명의 구성요소인 당귀(Angelica gigas)는 진정, 진통, 정혈, 강장의 목적으로 이용되고 있으며, 특히 진정, 통경 작용에 의하여 빈혈증과 부인병 등에 산후요약으로 쓰이는 생약이다. 우리나라에서는 참당귀의 건조된 뿌리를 당귀로 사용하며, 대한약전에서도 당귀의 기원식물로 수재되어 있다. Angelica gigas, which is a component of the present invention, is used for the purpose of sedation, analgesia, blood donation, and tonic, and is particularly used as a postpartum medicine for anemia and gynecology due to sedation and pain. In Korea, the dried root of Angelica gigas is used as a donkey, and the Korean Pharmacopoeia is also planted as a plant of origin.
본 발명의 구성요소인 산수유(Cornus officinalis Sieb. et Zucc.)는 층층나무과 목본식물의 과육으로 보고된 성분으로는 코닌(cornin), 종자의 지방유로 팔미틴산, 올레인산, 리놀산 등이 있다. 항균, 이뇨, 혈압강하의 약리작용이 있고, 과육의 코닌은 독성은 매우 낮고 용혈작용은 없고 비교적 약하기는 하지만 부교감신경 흥분작용이 있다고 알려져 있다. Cornus officinalis Sieb. Et Zucc. Is a component of the present invention is reported as a pulp of a dogwood tree plant as cornin (cornin), the fatty oil of seeds include palmitic acid, oleic acid, linoleic acid and the like. Antibacterial, diuretic, blood pressure-lowering pharmacological action, flesh pulp is known to have a low toxicity, no hemolytic action, relatively weak but parasympathetic nerve stimulation.
본 발명의 구성요소인 선복화는 국화과의 다년생 초본인 금불초(Inula britannica L. var. chinensis (Rupr.) Reg.) 및 동속 근연식물의 두화(頭花)로 여름과 가을에 막 피기 시작한 화서(花序)를 채집해서 햇볕에 말려 사용한다. 보고된 성분으로는 퀘르세틴(quercetin), 이소퀘르세틴(isoquercetin), 카페인산(caffeic acid), 클로로젠산(cholorogenic acid) 및 이눌린(inulin), 타라사스테롤(taraxasterol)과 같은 스테리올(steriol)성분이 알려져 있다. 카페인산과 클로로젠산에는 광범위한 항균작용이 있다고 알려져 있고, 래트에 경구투여하면 중추신경의 흥분성을 높이고 사람의 위에서는 염산분비량을 증가시킨다고 알려 져 있다.Seonhwa, a constituent of the present invention, is an inflorescence perennial herbaceous perennial herbaceous flower ( Inula britannica L. var. Chinensis (Rupr.) Reg.) And inflorescences that have just started blooming in summer and autumn. Collect 花序 and dry it in the sun. Reported ingredients include steriols such as quercetin, isoquercetin, caffeic acid, cholorogenic acid, and inulin and taraxasterol Ingredients are known. Caffeic acid and chlorogenic acid are known to have a wide range of antimicrobial activities. Oral administration of rats is known to increase the excitability of the central nervous system and increase the amount of hydrochloric acid in the stomach of humans.
본 발명의 구성요소인 측백엽은 측백나무과의 측백나무(Biota orientalis (L.) Endl.) 의 어린가지와 잎을 말하며 봄, 가을에 채집하여 햇볕에 말려 사용한다. 잎에는 에젠셜 오일(essential oil), 플라보노이드, 탄닌 등이 함유되어 있음이 보고되어 있고, 경혈, 지혈, 거풍습, 혈리, 단독, 고혈압, 세균성이질 등의 치료 및 한서를 견디고 새살을 나게 하는등의 효능이 있다고 알려져 있다. 측백엽 추출물로 알콜성 사포닌은 거담작용, 페놀성 글리코사이드는 진해작용이 있는 것으로 알려져 있고, 아세틸콜린의 작용을 부분적으로 차단할수 있다고 알려져 있다.The cypress lobe, which is a component of the present invention, refers to the sprigs and leaves of the cypress ( Biota orientalis (L.) Endl.), And is collected in spring and autumn and used in the sun. It is reported that the leaves contain essential oils, flavonoids, tannins, etc., and they also treat acupuncture points, hemostasis, epidemics, hemostasis, isolation, hypertension, bacterial dysfunction, etc. It is known to be effective. It is known that alcoholic saponins have expectorant action, phenolic glycosides have antitussive effect, and that they may partially block the action of acetylcholine.
본 발명의 구성요소인 갈근은 콩과의 다년생 경엽식물인 칡(Pueraria thunbergiana (Sieb. et Zucc) Benth.) 의 뿌리로 봄,가을에 캐어 외피를 벗겨 물에 불려 썰어 햇볕에 말린 것을 말한다. 보고된 성분으로는 이소플라본(isoflavone)인 푸에라린(puerarin), 푸에라인 자일로사이드(puerarin xyloside), 다이드제인(daidzein), β-시토스테롤외에 다량의 전분이 함유되어 있는 것으로 알려져 있고, 순환계통에 작용하여 뇌 및 관상동맥의 혈류량을 증가시키고, 다이드제인은 히스타민 및 아세틸콜린의 작용에 대해 길항한다고 알려져 있고, 소갈, 이질, 고혈압, 협심증, 난청의 치료제로 이용된다. The root of the present invention is the root of the root of Pueraria thunbergiana (Sieb. Et Zucc) Benth., A perennial foliage plant of legumes, and refers to dried sun-dried by peeling the outer skin in spring and autumn. The components reported are known to contain a large amount of starch in addition to isoflavones puerarin, puerarin xyloside, daidzein, and β-sitosterol. It is known to act on the circulatory system to increase blood flow in the brain and coronary arteries, and Dyzezein is known to antagonize the action of histamine and acetylcholine, and is used as a treatment for sodium, dysentery, hypertension, angina and deafness.
본 발명의 구성요소인 천마(Gastrodia elata Blume)는 난초과의 다년생 기생초본으로 경엽을 가을에서 이듬해 봄사이에 채집하여 사용한다. 보고된 성분으로는 가스트로딘(gastrodin), p-히드록시벤질알콜, β-시토스테롤, 다우코스테롤 등이 알려져있다. 강장,진정, 류마티스성 관절염, 반신불수, 어언장애의 치료목적으로 사용된다. Gastrodia elata Blume, which is a component of the present invention, is a perennial parasitic herb of the orchid family, and the foliage is collected and used between autumn and spring. The reported components are known as gastrodin, p -hydroxybenzyl alcohol, β-sitosterol, dowsterol and the like. It is used for the treatment of tonic, soothing, rheumatoid arthritis, paraplegia and speech disorder.
본 발명의 구성요소인 구기자는 가지과의 덩굴성관목인 구기자나무(Lycium chinense Mill.)의 성숙한 열매로 카로텐(carotene), 비타민 B, C, 리놀레산(linoleic acid), β-시토스테롤 등이 성분으로 알려져 있다. 혈당 및 콜레스테롤의 강하작용, 혈청과 간에서 단백직을 증가시키고, 부교감신경을 흥분시키고, 혈압강하등의 약리활성을 가지고 있다. 소갈, 어지러움, 현기증등에 치료 목적으로 이용된다. Goji, which is a component of the present invention, is a mature fruit of Lycium chinense Mill. . It lowers blood sugar and cholesterol, increases protein protein in serum and liver, excites parasympathetic nerves, and has pharmacological activities such as lowering blood pressure. It is used for the purpose of treatment for exhaustion, dizziness and dizziness.
본 발명의 구성요소인 삼백초, 오미자, 돌미나리, 당귀, 산수유, 선복화, 측백엽, 갈근, 천마 및 구기자 각각은 본 발명자들의 연구에 의해 각각의 생약이 인지 기능 개선 효과가 있음을 확인하였다. 그러나, 이들 각각의 생약을 단독으로 사용할 경우 인지 기능 개선 효과가 임상에 적용할 정도까지 이르지 못하였다. 본 발명자들은 각각의 생약의 작용 메카니즘이 상이한 것에 착안하여 이들을 조합하여 조성물로 사용함으로써 각각의 생약 단독 사용에 비하여 이들의 2종 이상, 바람직하게는 3종의 생약의 복합 조성물 사용시 임상에 적용할 정도까지 상승 효과를 나타냄을 확인하였다. Each of the components of the present invention, the three hundred seconds, Schisandra chinensis, parsley, Angelica, cornus, periwinkle, baekryeop, brown root, Cheonma and Gugija each of the inventors of the present inventors confirmed that each herbal medicine has an effect on improving cognitive function. However, the use of each of these herbs alone did not reach the effect of improving cognitive function. The inventors pay attention to the different mechanisms of action of each herbal medicine, and use them in combination, so that they can be clinically applied when using a combination composition of two or more thereof, preferably three herbal medicines, compared to the use of each herbal medicine alone. It was confirmed that the synergy effect until.
본 발명의 조성물중 생약의 함량은 삼백초, 오미자, 돌미나리, 당귀, 산수유, 선복화, 측백엽, 갈근, 천마 및 구기자중 이들 각각의 생약을 1∼5중량부의 비율로 배합하는 것이 바람직하다. 상기 함량 비율을 벗어나면, 본 발명의 인지 기능 효과의 상승을 기대하기가 어려워 바람직하지 못하다. The content of the herbal medicine in the composition of the present invention is preferably blended at a ratio of 1 to 5 parts by weight of each of these herbal medicines among the three hundred seconds, Schisandra chinensis, parsley, Angelica, Cornus, Sesame, Sesame leaf, Brown root, Cheonma and Gugija. If it is out of the content ratio, it is difficult to expect the increase in the cognitive function effect of the present invention is not preferable.
본 발명의 조성물은 삼백초, 오미자, 돌미나리, 당귀, 산수유, 선복화, 측백 엽, 갈근, 천마 및 구기자중 2종 이상의 생약의 추출물만을 함유할 수 있으나, 투여의 용이를 위해 약제학적으로 허용되는 공지의 담체 등을 포함할 수 있다. The composition of the present invention may contain only extracts of two or more of the herbal medicines of three hundred seconds, Schisandra chinensis, parsley, Angelica, Cornus, Sesame, Lactobacillus, Root, Cheonma and Gugija, but are pharmaceutically acceptable for easy administration. And carriers.
본 발명의 조성물은 약제학적 분야에서 공지의 방법의 의해 제제화될 수 있고, 그 자체 또는 약제학적으로 허용되는 담체, 부형제 등과 혼합하여 약제학적으로 통상으로 허용되는 약학적 제제, 예를 들면 액제, 시럽제, 캡슐제 등으로 제제화될 수 있으며, 이들은 경구 또는 비경구로 투여될 수 있다. The compositions of the present invention may be formulated by methods known in the pharmaceutical art, and may be mixed with themselves or with a pharmaceutically acceptable carrier, excipient, and the like to be a pharmaceutically conventionally acceptable pharmaceutical agent such as a liquid or a syrup. , Capsules and the like, which can be administered orally or parenterally.
상기 본 발명의 조성물을 포함하는 액제, 캡슐제 등은 건강보조식품으로 사용하는 것이 바람직하며, 본 발명에서 사용된, 용어 "건강보조식품"이라 함은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀제, 분말제, 과립제, 액상제, 환제 등의 형태로 제조 가공한 건강식품 또는 음료, 요구르트, 치즈 등의 기능성 식품을 말한다.The liquid, capsules and the like comprising the composition of the present invention is preferably used as a health supplement, and the term "health supplement" used in the present invention is used as a raw material or ingredient having a useful functionality to the human body. Refers to functional foods such as health foods or beverages, yogurt, cheese, etc. manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills and the like.
본 발명의 조성물은 체내에서 활성성분의 흡수도, 배설속도, 환자의 연령 및 체중, 성별 및 상태, 치료할 질병의 중증정도 등에 따라 적절히 선택되나, 일반적으로 성인에게 1일 0.01∼500mg/kg, 바람직하게는 0.1∼200mg/kg으로 투여하는 것이 바람직하다. 이렇게 제형화된 단위투여형 제제는 필요에 따라 일정시간 간격으로 수회 투여할 수 있다. The composition of the present invention is appropriately selected according to the absorption of the active ingredient in the body, the rate of excretion, the age and weight of the patient, the sex and condition, the severity of the disease to be treated, etc., but generally in adults 0.01 to 500 mg / kg, per day Preferably, the dosage is 0.1 to 200 mg / kg. The unit dosage form so formulated may be administered several times at regular time intervals as needed.
본 발명의 조성물은 우수한 뇌기능 및 인지 기능 개선 효과를 나타내며, 이를 위해서 알콜 추출물을 자체를 투여하는 것으로 충분하지만, 유효성분의 함량을 증가시켜 더 우수한 효과를 얻기 위해, 상기 추출물을 유기용매 또는 물로 분획하거나, 컬럼크로마토그래피하여 제조한 분획물을 투여할 수도 있다. 상기 분획물을 제조하기 위한 유기용매로는 생약 추출물을 분획할 때 사용되는 통상의 용매, 예컨대, 헥산, 에테르, 에틸아세테이트, 클로로포름, 디클로로메탄, 벤젠, 아세톤 등을 사용할 수 있고, 컬럼크로마토그래피는 통상의 컬럼크로마토그래피, 예컨대, HP-20 컬럼크로마토그래피를 사용할 수 있다. The composition of the present invention shows an excellent brain function and cognitive improvement effect, for this purpose it is enough to administer the alcohol extract itself, but to increase the content of the active ingredient to obtain a better effect, the extract with an organic solvent or water Fractions or fractions prepared by column chromatography may be administered. As an organic solvent for preparing the fractions, conventional solvents used for fractionating herbal extracts, such as hexane, ether, ethyl acetate, chloroform, dichloromethane, benzene, acetone, and the like, may be used. Column chromatography, such as HP-20 column chromatography, may be used.
이하, 본 발명을 하기 실시예를 통하여 더욱 상세히 설명한다. 이들 실시예는 본 발명의 예시 목적을 위한 것이며, 본 발명의 보호범위를 제한하고자 하는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. These examples are for illustrative purposes of the present invention and are not intended to limit the protection scope of the present invention.
실시예 1~42. 본 발명의 알콜 추출물의 제조Examples 1 to 42. Preparation of Alcohol Extracts of the Invention
삼백초, 오미자, 돌미나리, 당귀, 산수유, 선복화, 측백엽, 갈근, 천마 및 구기자중 2종 이상의 생약을 하기 표 1과 같이 취해 70% 에탄올을 가하여 환류냉각장치하에서 환류추출하였다. 추출물을 여과한 후 감압회전농축기에서 농축하여 하기의 에탄올 총 추출물을 얻었다. 에탄올 추출물은 평균 건조중량의 15∼25%의 추출물을 얻을 수 있었다.Two or more kinds of herbal medicines among three hundred sec, Schisandra chinensis, parsley, Angelica, Cornus, Sesame, Sesame, Root, Cheonma and Goji were taken as shown in Table 1 below, and 70% ethanol was added to reflux under reflux cooling. The extract was filtered and concentrated in a vacuum rotary concentrator to obtain the following ethanol total extract. The ethanol extract was able to obtain an extract of 15-25% of the average dry weight.
표 1 (단위 : kg) Table 1 (Unit: kg)
(계속)(continue)
실시예 43∼52. 활성분획물 제조Examples 43-52. Active fraction preparation
상기 실시예 12의 추출물로부터 활성성분의 농도가 더 높은 분획을 제조하기 위해 HP-20 컬럼 크로마토그래피를 시행하였다. 상기 실시예 12의 총 추출물을 적량의 물에 현탁한 후 물로 충진한 HP-20 컬럼에 흘려 물분획(HP-E00)을 얻었다. 이후 에탄올의 함량을 20%씩 증가시키면서 실시예 43∼47의 분획(HP-E20, HP-E40, HP-E60, HP-E80 및 HP-E)을 얻었다. 각 분획들은 감압농축기하에서 농축하여 분획농축물을 얻었다. 각 분획의 수율은 HP-E20 (17%), HP-E40 (12%), HP-E60 (14%), HP-E80 (16%) 및 HP-E (9%) 였다. HP-20 column chromatography was performed to prepare a fraction of higher concentration of the active ingredient from the extract of Example 12. The total extract of Example 12 was suspended in an appropriate amount of water and then flowed into an HP-20 column filled with water to obtain a water fraction (HP-E00). Then, fractions of Examples 43 to 47 (HP-E20, HP-E40, HP-E60, HP-E80, and HP-E) were obtained while increasing the content of ethanol by 20%. Each fraction was concentrated under reduced pressure concentrator to obtain fraction concentrate. Yield of each fraction was HP-E20 (17%), HP-E40 (12%), HP-E60 (14%), HP-E80 (16%) and HP-E (9%).
실시예 19의 추출물도 상기의 방법으로 실시예 48∼52의 분획(HP-E25, HP-E45, HP-E65, HP-E85 및 HP-H)을 얻었다. 각 분획의 수율은 HP-E25 (28%), HP-E45 (12%), HP-E65 (11%), HP-E85 (15%) 및 HP-H (10%) 였다. The extract of Example 19 also obtained the fractions of Examples 48 to 52 (HP-E25, HP-E45, HP-E65, HP-E85 and HP-H) by the above method. The yield of each fraction was HP-E25 (28%), HP-E45 (12%), HP-E65 (11%), HP-E85 (15%) and HP-H (10%).
비교예 1∼10. 단일 생약 추출물의 제조Comparative Examples 1 to 10. Preparation of Single Herb Extract
5kg의 삼백초, 오미자, 돌미나리, 당귀, 산수유, 선복화, 측백엽, 갈근, 천마 및 구기자 10종의 생약 각각을 70% 에탄올을 가하여 환류냉각장치하에서 환류추출하였다. 추출물을 여과한 후 감압회전농축기에서 농축하여 삼백초 추출물(비교예 1), 오미자 추출물(비교예 2), 돌미나리 추출물(비교예 3), 당귀 추출물(비교예 4), 산수유 추출물(비교예 5), 선복화 추출물(비교예 6), 측백엽 추출물(비교예 7), 갈근 추출물(비교예 8), 천마 추출물(비교예 9) 및 구기자 추출물(비교예 10) 을 각각 얻었다. 각각의 추출물은 각 생약 건조중량의 15∼25% 정도 얻을 수 있었다.Five kilograms of three hundred vinegar, Schisandra chinensis, parsley, Angelica, Cornus, Sesame, Caesar, Gallus, Cheonma, and Gojija were each refluxed under reflux cooling with 70% ethanol. The extract was filtered and concentrated in a vacuum rotary concentrator to extract three hundred seconds extract (Comparative Example 1), Schisandra chinensis extract (Comparative Example 2), Parsley extract (Comparative Example 3), Angelica extract (Comparative Example 4), Cornus extract (Comparative Example 5) , Sesame extract (Comparative Example 6), Cerebral Locust Extract (Comparative Example 7), Carrot Root Extract (Comparative Example 8), Chunma Extract (Comparative Example 9) and Goji berry extract (Comparative Example 10) were obtained, respectively. Each extract was about 15-25% of the dry weight of each herbal medicine.
조성물예Composition example
조성물예 1. 캡슐제의 제조 Composition Example 1 Preparation of Capsule
실시예 1의 추출물 100mg100 mg of extract of Example 1
유당 100mgLactose 100mg
전분 93mgStarch 93mg
탈클 2mgTackle 2mg
스테아린산 마그네슘 적량Magnesium stearate proper amount
상기의 성분을 혼합하고 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충진하여 캡슐제를 제조한다.The capsules are prepared by mixing the above components and filling gelatin capsules according to a conventional method for preparing capsules.
조성물예 2. 캡슐제의 제조 Composition Example 2 Preparation of Capsule
실시예 12의 추출물 200mg200 mg of extract of Example 12
유당 100mgLactose 100mg
전분 93mgStarch 93mg
탈클 2mgTackle 2mg
스테아린산 마그네슘 적량Magnesium stearate proper amount
상기의 성분을 혼합하고 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충진하여 캡슐제를 제조한다.The capsules are prepared by mixing the above components and filling gelatin capsules according to a conventional method for preparing capsules.
조성물예 3. 액제의 제조 Composition Example 3 Preparation of Liquid
실시예 2의 추출물 200mg200 mg of extract of Example 2
설탕 20g20 g of sugar
이성화당 20g20 g of isomerized sugar
레몬향 적량Lemon flavor
정제수를 가하여 전체 100mlAdd 100 ml of purified water
상기의 성분을 통상의 액제의 제조방법에 따라서 혼합하고 100ml의 갈색병에 충진하고 멸균시켜서 액제를 제조한다.The above components are mixed according to a conventional method for preparing a liquid, and filled into 100 ml brown bottles and sterilized to prepare a liquid.
조성물예 4. 액제의 제조 Composition Example 4 Preparation of Liquid
실시예 19의 추출물 300mg300 mg of extract of Example 19
설탕 20g20 g of sugar
이성화당 20g20 g of isomerized sugar
레몬향 적량Lemon flavor
정제수를 가하여 전체 100mlAdd 100 ml of purified water
상기의 성분을 통상의 액제의 제조방법에 따라서 혼합하고 100ml의 갈색병에 충진하고 멸균시켜서 액제를 제조한다.The above components are mixed according to a conventional method for preparing a liquid, and filled into 100 ml brown bottles and sterilized to prepare a liquid.
조성물예 5. 음료의 제조Composition Example 5 Preparation of Beverage
실시예 42의 추출물 5 중량%와 식용색소 0.05 중량%, 오렌지 에센스 0.05 중량%, 과당 5.0 중량%, 구연산 0.1중량%, 비타민 C 0.05 중량%를 포함하는 일반 기능성 음료 베이스를 첨가한 조성물을 제조한 다음, 정제수를 첨가하여 음료를 제조하였다. 5 wt% extract of Example 42, 0.05 wt% food coloring, 0.05 wt% orange essence, 5.0 wt% fructose, 0.1 wt% citric acid, 0.05 wt% vitamin C prepared a composition containing a general functional beverage base Next, purified water was added to prepare a beverage.
실험예 1. 뇌신경세포 보호 활성 평가Experimental Example 1. Evaluation of neuronal neuroprotective activity
실험동물Laboratory animals
Sprague-Dawley계 흰쥐를 서울대학교 동물사육장에서 공급받아 서울대학교 약학대학 실험동물실에서 사육하였다. 사육장의 환경은 실내온도를 22 ± 5℃로 유지하고 조명시간을 아침 7시에서 저녁 7시로 고정하였으며, 사료는 조단백 23.2%, 조지방 4.0%, 조섬유 6.0%, 조회분 10.0%, 조칼슘 0.6%, 조인 0.4% 등이 함유된 고형사료 (서울, 삼양사)를 사용하였다. Sprague-Dawley rats were supplied from the Seoul National University Animal Breeding Farm and were bred in the experimental animal laboratory of the College of Pharmacy, Seoul National University. The environment of the kennel was kept at 22 ± 5 ℃ and the lighting time was fixed from 7 am to 7 pm, and the feed was 23.2% crude protein, 4.0% crude fat, 6.0% crude fiber, 10.0% crude ash and 0.6% crude calcium. Solid feed (Seoul, Samyang) containing 0.4% was used.
흰쥐의 대뇌피질세포의 분리 및 배양Isolation and Culture of Cerebral Cortical Cells in Rats
상기 흰쥐 태자의 대뇌 부분만을 적출하여 해부현미경 밑에서 조심스럽게 뇌막(meninges)을 제거한 후 대뇌조직을 0.25% 트립신으로 30분 동안 처리하여 조직을 연화시켜 개개의 세포로 유리되도록 하였다. 분리한 대뇌피질세포를 2.0 ×105 cells/dish가 되게 하여 폴리-L-라이신으로 도포한 배양 용기 (Falcon, 15 ×24 mm)에 이식하였다. 배양액은 DMEM 90%, 소태아혈청(fetal calf serum) 10%, 페니 실린 100 IU/ml과 스트렙토마이신 100 g/ml으로 구성된 배양액을 사용하였다. 세포의 배양은 37℃ 배양기에서 공기(95%)와 CO2(5%)의 혼합기체를 계속 공급하면서 수행하였으며 배양 4일이 지난 후 5 ×10-5M 5-플루오로데옥시우리딘으로 처리하여 신경세포가 아닌 다른 세포의 성장을 억제시켰다(Choi, D. W. (1985) Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci. Lett. 58: 293-297).Only the cerebral portion of the rat fetus was removed, and the meninges were carefully removed under the dissecting microscope, and the cerebral tissues were treated with 0.25% trypsin for 30 minutes to soften the tissues and liberated into individual cells. The isolated cerebral cortical cells were transplanted into a culture vessel (Falcon, 15 × 24 mm) coated with poly-L-lysine at 2.0 × 10 5 cells / dish. The culture medium was composed of 90% DMEM, 10% fetal calf serum, 100 IU / ml penicillin and 100 g / ml streptomycin. Cultivation of the cells was carried out in a 37 ℃ incubator while continuously supplying a mixture of air (95%) and CO 2 (5%), and after 4 days of culture to 5 × 10 -5 M 5-fluorodeoxyuridine Treatment inhibited the growth of cells other than neurons (Choi, DW (1985) Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci. Lett . 58: 293-297).
시료의 투여Dosing of the sample
상기 실시예 1∼52의 추출물 및 비교예 1∼10의 생약 추출물을 DMSO (최종농도 0.1% 이내)에 용해시킨 후 증류수로 희석하여 1mg/ml의 농도로 제조한 다음 millipore membrane (0.22 μm, Millex-GV, U.S.A.)을 통과시켜 무균상태로 만들어 시료를 제조하였다. 상기에서 분리된 흰쥐의 대뇌피질세포를 20일간 배양한 후 각각의 시료를 상기의 각 dish에 50μg/ml, 100μg/ml의 농도로 투여하였다. The extracts of Examples 1 to 52 and the herbal extracts of Comparative Examples 1 to 10 were dissolved in DMSO (within 0.1% final concentration) and then diluted with distilled water to prepare a concentration of 1 mg / ml, followed by millipore membrane (0.22 μm, Millex -GV, USA) to make the sample as sterile. After culturing the cerebral cortical cells of the isolated rats for 20 days, each sample was administered at the concentration of 50μg / ml, 100μg / ml in each dish.
뇌신경세포 보호 활성 - MTT assayCerebral nerve cell protective activity-MTT assay
상기 시료 투여 1시간 후에 50μM 글루타메이트로 신경독성을 유발시켰다. 신경독성 유발 30분 후에 배양액을 DMEM으로 갈아준 후 실시예 1∼52 및 비교예 1∼10의 각각의 시료를 다시 동일량을 투여하고 24시간 더 배양하였다(Throughout treatment). 배양 중인 대뇌피질세포의 배양액에 MTT (1mg/ml)를 배양액의 10%가 되도록 가하고 계속하여 3시간 더 배양한 후 생성된 formazan을 DMSO로 녹여낸 다음 540nm에서 흡광도를 측정하였고(Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immuno. Methods 65: 55-61), 그 결과를 하기 표 2에 나타내었다. Neurotoxicity was induced with 50 μM glutamate 1 hour after the sample administration. After 30 minutes of induction of neurotoxicity, the culture medium was changed to DMEM, and the same amount of each sample of Examples 1 to 52 and Comparative Examples 1 to 10 was again administered, and further cultured for 24 hours (Throughout treatment). MTT (1mg / ml) was added to 10% of the culture medium in the cultured cerebral cortical cells, and after further incubation for 3 hours, the produced formazan was dissolved in DMSO and absorbance was measured at 540 nm (Mosmann, T. ( 1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immuno.Methods 65: 55-61), and the results are shown in Table 2 below.
표 2TABLE 2
(계속)(continue)
상기 표 2와 같이 본 발명의 실시예 1∼52의 조성물은, 글루타메이트로 독성 을 유도한 흰쥐의 일차배양 대뇌피질세포에 대해 뇌신경세포 보호 활성을 나타내었으며, 특히 실시예 11∼13과 19의 추출물 및 43∼52의 분획물이 높은 활성을 나타내었다. As shown in Table 2, the compositions of Examples 1 to 52 of the present invention showed neuroprotective activity against the primary cultured cerebral cortical cells of rats induced by toxicity with glutamate, and particularly the extracts of Examples 11 to 13 and 19. And fractions 43-52 showed high activity.
실험예 2. 인지기능 개선 활성 평가Experimental Example 2. Evaluation of cognitive function improving activity
수동적 회피반응 시험 (Passive avoidance test)Passive avoidance test
하단에 두께 3mm의 스테인레스 막대가 0.5cm 간격으로 설치된 회피상자(40 ×20 ×20 cm)를 밝은 방과 어두운 방으로 나누고 밝은 방에 넣은 생쥐가 어두운 방으로 옮겨가면 밝은 방과 어두운 방을 나누는 문이 닫히는 동시에 스테인레스 막대를 통하여 0.1 mA/10g 체중의 전기자극이 주어지는 훈련을 시켰다. 24 시간 후 동일한 시험을 실시하여 생쥐가 밝은 방에 머무르는 시간을 측정하여 이를 전일의 훈련에 대한 기억의 지표로 삼았다. 치매 유발을 위한 스코폴라민(scopolamine)은 1.5 mg/kg 체중의 농도로 용액을 제조하여 훈련시행 30 분전에 피하 주사하여 치매를 유발시켰으며, 스코폴라민 투여 1시간 전에 실시예 1∼52의 추출물을 각각 10mg/kg의 용량으로 복강 내 주사하여 스코폴라민에 의해 유도되는 치매에 어떻게 영향을 미치는지를 알아보았다. 복합조성물의 인지기능 개선활성은 Passive Avoidance Test를 이용하여 평가하였다. 양성대조군으로 벨나크린(velnacrine, AChE 저해제)을 사용하였으며 실험결과는 표 3과 같다.The avoidance box (40 × 20 × 20 cm) with a 3mm-thick stainless steel bar at the bottom is divided into a bright room and a dark room, and when the mouse in the bright room is moved to the dark room, the door separating the bright and dark rooms is closed. At the same time, training was given to give electric stimulation of 0.1 mA / 10 g body weight through a stainless rod. The same test was performed after 24 hours to determine how long the mice stayed in the bright room, which was used as an indicator of memory for the previous day's training. Scopolamine for dementia-induced dementia was injected into the solution at a concentration of 1.5 mg / kg body weight and injected subcutaneously 30 minutes before training, and in Examples 1 to 52 one hour before scopolamine administration. Intraperitoneal injections of extracts at doses of 10 mg / kg each were investigated to determine how they affect dementia induced by scopolamine. The cognitive improvement activity of the composite composition was evaluated using the Passive Avoidance Test. Velacrine (velnacrine, AChE inhibitor) was used as a positive control, and the experimental results are shown in Table 3.
표 3TABLE 3
(계속)(continue)
표 3과 같이 본 발명의 실시예 1∼52의 조성물은 비교예에 비하여 우수한 인 지 기능 개선 효과를 나타내었다. As shown in Table 3, the compositions of Examples 1 to 52 of the present invention showed an excellent effect of improving the recognition function compared to the comparative example.
이상에서 알 수 있는 바와 같이, 본 발명의 삼백초, 오미자, 돌미나리, 당귀, 산수유, 선복화, 측백엽, 갈근, 천마 및 구기자로 이루어진 군에서 선택되는 2종 이상의 생약의 알콜 추출물을 포함하는 조성물은 뇌기능 및 인지 기능 개선 활성이 우수하여, 치매 등의 퇴행성 뇌신경계 질환, 특히 노인성 치매 등에 유용하게 사용할 수 있다. As can be seen from the above, the composition comprising an alcoholic extract of two or more herbal medicines selected from the group consisting of three hundred seconds, Schisandra chinensis, parsley, Angelica, Cornus, Sesameum, Lilium, Root, Cheonma and Goji It is excellent in function and cognitive function improving activity, and can be usefully used for degenerative cerebral nervous system diseases such as dementia, especially senile dementia.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020020042740A KR100569089B1 (en) | 2002-07-20 | 2002-07-20 | Composition having brain function and congnition enhancing activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020020042740A KR100569089B1 (en) | 2002-07-20 | 2002-07-20 | Composition having brain function and congnition enhancing activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20040008975A KR20040008975A (en) | 2004-01-31 |
| KR100569089B1 true KR100569089B1 (en) | 2006-04-10 |
Family
ID=37317952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020020042740A KR100569089B1 (en) | 2002-07-20 | 2002-07-20 | Composition having brain function and congnition enhancing activity |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100569089B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101222603B1 (en) | 2010-03-18 | 2013-01-16 | 경희대학교 산학협력단 | Composition comprising Thuja orientalis leaves for preventing or treating of neurodegenerative disease |
| CN104880521A (en) * | 2015-02-02 | 2015-09-02 | 江苏省中医药研究院 | Identification method for judging whether Chinese angelica undergoes sulfur fumigation |
| KR20210131039A (en) | 2020-04-23 | 2021-11-02 | 주식회사 케이제이엠바이오 | Composition of Nutrient Delivery System for Improving Brain Function |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100950254B1 (en) * | 2008-01-18 | 2010-03-31 | 에스케이임업 주식회사 | Composition having congnition enhancing activity comprising Betula Platy Phylla extract |
| KR101877290B1 (en) * | 2016-10-14 | 2018-07-11 | 주식회사 팜크로스 | Aroma composition with grape flavor containing essential oil of Schisandra chinensis and Angelica gigas for enhancing concentration state and uses thereof |
| KR102499893B1 (en) * | 2020-06-17 | 2023-02-15 | 파마코바이오 주식회사 | Pharmaceutical composition comprising a fraction of Saururus chinensis and method for preparing the same |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000002474A (en) * | 1998-06-20 | 2000-01-15 | 신민규 | Preventive and therapeutic agent for degenerative cerebrum neurological disease |
| KR20020030642A (en) * | 2000-10-19 | 2002-04-25 | 주식회사엘컴바이오테크놀러지 | Pharmaceutical prepareations containing a dibenzocyclooctane lignan derivative for prevention and treatment of ischemic stroke by blocking neuronal cell death |
| KR20020030648A (en) * | 2000-10-19 | 2002-04-25 | 주식회사엘컴바이오테크놀러지 | Saururus chinensis extract for prevention and treatment of neurodegenerative disease and pharmaceutical preparations containing the same |
| KR20020038381A (en) * | 2000-11-17 | 2002-05-23 | 이응세 | A crude drug composition for promoting learning and memory which contains Lycii fructus extract as an effective ingredient |
-
2002
- 2002-07-20 KR KR1020020042740A patent/KR100569089B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000002474A (en) * | 1998-06-20 | 2000-01-15 | 신민규 | Preventive and therapeutic agent for degenerative cerebrum neurological disease |
| KR20020030642A (en) * | 2000-10-19 | 2002-04-25 | 주식회사엘컴바이오테크놀러지 | Pharmaceutical prepareations containing a dibenzocyclooctane lignan derivative for prevention and treatment of ischemic stroke by blocking neuronal cell death |
| KR20020030648A (en) * | 2000-10-19 | 2002-04-25 | 주식회사엘컴바이오테크놀러지 | Saururus chinensis extract for prevention and treatment of neurodegenerative disease and pharmaceutical preparations containing the same |
| KR20020038381A (en) * | 2000-11-17 | 2002-05-23 | 이응세 | A crude drug composition for promoting learning and memory which contains Lycii fructus extract as an effective ingredient |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101222603B1 (en) | 2010-03-18 | 2013-01-16 | 경희대학교 산학협력단 | Composition comprising Thuja orientalis leaves for preventing or treating of neurodegenerative disease |
| CN104880521A (en) * | 2015-02-02 | 2015-09-02 | 江苏省中医药研究院 | Identification method for judging whether Chinese angelica undergoes sulfur fumigation |
| KR20210131039A (en) | 2020-04-23 | 2021-11-02 | 주식회사 케이제이엠바이오 | Composition of Nutrient Delivery System for Improving Brain Function |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040008975A (en) | 2004-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Phamiwon et al. | Diabetes and medicinal benefits of Passiflora edulis | |
| KR102620997B1 (en) | Composition for protecting eyesight or improving and preventing retinal diseases comprising extracts of stewartia pseudocamellia maxim | |
| KR102022263B1 (en) | A composition comprising the fermented extract of Cinnamomum verum J. Presl, Ulmus davidiana var. japonica da and Acanthopanax sessiliflorum Seeman for preventing and treating benign prostatic hyperplasia | |
| KR101794006B1 (en) | Anti inflammatory comprising plant extract | |
| WO2016190566A9 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
| KR20090084435A (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of houttuynia cordata thub and ulmus davidana var.japonica as an active ingredient | |
| KR100569089B1 (en) | Composition having brain function and congnition enhancing activity | |
| KR100991399B1 (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of Houttuynia Cordata, Centella asiatica, Plantago asiatica, Ulmus davidana var. Japonica and Morus alba L. as an active ingredient | |
| KR101821925B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
| US10806766B2 (en) | Method for treating, preventing, or alleviating osteoporosis | |
| KR101436213B1 (en) | Compositions for prevention and/or treatment of obesity comprising extracts of Boehmeria sieboldiana | |
| KR101738206B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
| KR101248378B1 (en) | Pharmaceutical composition for arthritis treatment and prevention | |
| KR20110095765A (en) | Anti-allergic composition containing scrophularia buergeriana extract | |
| KR102624173B1 (en) | Composition comprising the extract of wild-simulated ginseng and Pyrus ussuriensis for immune-enhancement | |
| KR100538983B1 (en) | Pharmaceutical composition comprising the crude drug extract for improving liver function | |
| WO2024005224A1 (en) | Anti-obesity composition containing, as active ingredient, mixture of extracts of plant leaves including pine needles | |
| KR101307726B1 (en) | A composition comprising the extract of Angelica dahurica for preventing and treating drug intoxication or withdrawal symptoms | |
| KR102172371B1 (en) | A pharmaceutical composition comprising extract of Aloe, quince and corn silk for preventing or treating obesity | |
| KR100554948B1 (en) | Herbal composition for preventing and improving baldness | |
| KR20220103326A (en) | Composition for improvement, prevention or treatment of depression comprising herbal medicine mixture as effective component | |
| KR20150084405A (en) | Composition for Prevention and Treatment of Cardiovascular Diseases | |
| KR20230166330A (en) | Composition for inhibiting muscle contraction comprising extracts of herbal mixtures as an active ingredient | |
| KR20150050780A (en) | Compositions for prevention and treatment of obesity comprising Litsea japonica extracts or fraction thereof | |
| EP3449736A1 (en) | Composition for relieving menopausal symptom or osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| J201 | Request for trial against refusal decision | ||
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal | ||
| B701 | Decision to grant | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20130322 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20140306 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20150306 Year of fee payment: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20160329 Year of fee payment: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20170403 Year of fee payment: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20180403 Year of fee payment: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20190402 Year of fee payment: 14 |